Valuation — not yet established
No valuation for Genesis Therapeutics is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($327.4M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Genesis Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2023 | Early Stage VC (Series B) | $224.0M | ▮ | ▮ |
| Jun 2022 | Early Stage VC | $23.9M | ▮ | ▮ |
| Nov 2020 | Early Stage VC | $49.5M | ▮ | ▮ |
How Genesis Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Genesis Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Genesis Therapeutics raised?
- Genesis Therapeutics has raised $327.4M in total funding across 3 recorded rounds.
- When did Genesis Therapeutics last raise?
- Genesis Therapeutics last raised in Aug 2023 (Early Stage VC (Series B)), raising $224.0M.